You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Johnson and Johnson
Mallinckrodt
Express Scripts
Colorcon

Last Updated: March 1, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MEKINIST

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Mekinist

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01438554 Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma Active, not recruiting GlaxoSmithKline Phase 1 2011-10-01 The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study.
NCT01438554 Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma Active, not recruiting National Comprehensive Cancer Network Phase 1 2011-10-01 The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study.
NCT01438554 Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma Active, not recruiting Sidney Kimmel Comprehensive Cancer Center Phase 1 2011-10-01 The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study.
NCT01553851 GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer Completed National Comprehensive Cancer Network Phase 2 2013-02-01 This phase II trial studies how trametinib effects tumor cells in patients with oral cavity squamous cell carcinoma that can be removed by surgery. Trametinib may shrink the tumor by blocking an enzyme pathway needed for cell growth.
NCT01553851 GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer Completed Washington University School of Medicine Phase 2 2013-02-01 This phase II trial studies how trametinib effects tumor cells in patients with oral cavity squamous cell carcinoma that can be removed by surgery. Trametinib may shrink the tumor by blocking an enzyme pathway needed for cell growth.
NCT01827384 Molecular Profiling-Based Targeted Therapy in Treating Patients With Advanced Solid Tumors Recruiting National Cancer Institute (NCI) N/A 2013-12-01 This randomized pilot phase II trial studies molecular profiling-based targeted therapy in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment. WEE1 inhibitor MK-1775, everolimus, and trametinib are drugs that each target a specific variation in tumors by blocking different proteins needed for cell growth. Veliparib blocks an enzyme that helps repair deoxyribonucleic acid (DNA) damaged by chemotherapy, which may help chemotherapy drugs work better. It is not yet known whether testing patients for variations in their tumor and assigning treatment targeting the variation is more effective than standard non-targeted therapy in treating advanced solid tumors.
NCT01902173 Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer Suspended GlaxoSmithKline Phase 1/Phase 2 2013-07-01 This phase I/II trial studies the side effects and the best dose of Akt inhibitor GSK2141795 when given together with dabrafenib and trametinib and to see how well they work in treating patients with stage IIIC-IV cancer. Akt inhibitor GSK2141795, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving Akt inhibitor GSK2141795 with dabrafenib and trametinib may be a better treatment for cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Mekinist

Condition Name

Condition Name for Mekinist
Intervention Trials
Melanoma 12
Stage IV Skin Melanoma 6
Stage IIIC Skin Melanoma 6
Recurrent Melanoma 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Mekinist
Intervention Trials
Melanoma 24
Carcinoma 13
Lung Neoplasms 7
Carcinoma, Non-Small-Cell Lung 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Mekinist

Trials by Country

Trials by Country for Mekinist
Location Trials
United States 353
Canada 7
United Kingdom 6
Germany 5
France 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Mekinist
Location Trials
Texas 18
California 16
Ohio 15
Massachusetts 14
New York 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Mekinist

Clinical Trial Phase

Clinical Trial Phase for Mekinist
Clinical Trial Phase Trials
Phase 4 1
Phase 3 2
Phase 2/Phase 3 1
[disabled in preview] 66
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Mekinist
Clinical Trial Phase Trials
Recruiting 40
Not yet recruiting 18
Active, not recruiting 7
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Mekinist

Sponsor Name

Sponsor Name for Mekinist
Sponsor Trials
National Cancer Institute (NCI) 31
Novartis Pharmaceuticals 9
Novartis 7
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Mekinist
Sponsor Trials
Other 66
Industry 34
NIH 31
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Merck
Moodys
Express Scripts
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.